Pliant Therapeutics. has been granted a patent for integrin inhibitors, including crystalline forms of their phosphate salt. The patent details methods for preparing these forms and their potential use in treating fibrotic diseases, supported by specific X-ray powder diffraction data. GlobalData’s report on Pliant Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Pliant Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Pliant Therapeutics's grant share as of July 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Integrin inhibitors for treating fibrotic diseases
The granted patent US12018025B2 encompasses a series of claims related to various crystalline forms of specific salts of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid. The claims detail the unique characteristics of these crystalline forms, including their X-ray powder diffraction (XRPD) patterns, which feature distinct peak angles at 2-theta values. Additionally, the claims specify thermal properties determined by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA), highlighting endothermic peaks and weight loss percentages upon heating. The patent also describes methods for preparing these crystalline forms, which involve mixing the active compound with various acids in specific solvents, often under controlled temperature conditions.
Furthermore, the patent outlines the potential therapeutic applications of these crystalline forms, particularly in treating fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), liver fibrosis, and primary sclerosing cholangitis (PSC). The claims include methods for administering these crystalline forms to inhibit integrin activity, specifically targeting avß6 and avß1 integrins, which are implicated in fibrotic processes. The patent also mentions the formulation of pharmaceutical compositions containing these crystalline forms, along with instructions for their use in treating various fibrotic conditions, thereby providing a comprehensive framework for both the composition and application of these novel crystalline forms in medical treatments.
To know more about GlobalData’s detailed insights on Pliant Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
